UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2022
Commission File Number: 001-37891
AC IMMUNE SA
(Exact name of registrant as specified in its charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AC IMMUNE SA |
| |
| |
| By: | /s/ Andrea Pfeifer |
| | Name: | Andrea Pfeifer |
| | Title: | Chief Executive Officer |
| By: | /s/ Joerg Hornstein |
| | Name: | Joerg Hornstein |
| | Title: | Chief Financial Officer |
Date: May 25, 2022
EXHIBIT INDEX
Exhibit Number | Description |
99.1* | Invitation to the Ordinary Shareholders’ Meeting |
99.2* | 2022 Annual General Meeting Proxy Card |
99.3 | Consolidated Financial Statements (IFRS) as at and for the years ended December 31, 2021, 2020 and 2019 (incorporated by reference to Item 18 of Part III of AC Immune’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021 filed on March 22, 2022) |
99.4 | 2021 IFRS Consolidated Financial Statements (incorporated by reference to Exhibit 99.2 to the AC Immune Report of Foreign Private Issuer on Form 6-K filed on March 22, 2022) |
99.5 | 2021 Statutory Annual Report (incorporated by reference to Exhibit 99.3 to the AC Immune Report of Foreign Private Issuer on Form 6-K filed on March 22, 2022) |
99.6 | 2021 Compensation Report (incorporated by reference to Exhibit 99.4 to the AC Immune Report of Foreign Private Issuer on Form 6-K filed on March 22, 2022) |
* Filed herewith.